169 related articles for article (PubMed ID: 35046043)
1. Molecular basis of differential receptor usage for naturally occurring CD55-binding and -nonbinding coxsackievirus B3 strains.
Wang Q; Yang Q; Liu C; Wang G; Song H; Shang G; Peng R; Qu X; Liu S; Cui Y; Wang P; Xu W; Zhao X; Qi J; Yang M; Gao GF
Proc Natl Acad Sci U S A; 2022 Jan; 119(4):. PubMed ID: 35046043
[TBL] [Abstract][Full Text] [Related]
2. Interaction of decay-accelerating factor with coxsackievirus B3.
Hafenstein S; Bowman VD; Chipman PR; Bator Kelly CM; Lin F; Medof ME; Rossmann MG
J Virol; 2007 Dec; 81(23):12927-35. PubMed ID: 17804498
[TBL] [Abstract][Full Text] [Related]
3. The crystal structure of a coxsackievirus B3-RD variant and a refined 9-angstrom cryo-electron microscopy reconstruction of the virus complexed with decay-accelerating factor (DAF) provide a new footprint of DAF on the virus surface.
Yoder JD; Cifuente JO; Pan J; Bergelson JM; Hafenstein S
J Virol; 2012 Dec; 86(23):12571-81. PubMed ID: 22973031
[TBL] [Abstract][Full Text] [Related]
4. Variations of coxsackievirus B3 capsid primary structure, ligands, and stability are selected for in a coxsackievirus and adenovirus receptor-limited environment.
Carson SD; Chapman NM; Hafenstein S; Tracy S
J Virol; 2011 Apr; 85(7):3306-14. PubMed ID: 21270163
[TBL] [Abstract][Full Text] [Related]
5. Specificity of coxsackievirus B3 interaction with human, but not murine, decay-accelerating factor: replacement of a single residue within short consensus repeat 2 prevents virus attachment.
Pan J; Zhang L; Organtini LJ; Hafenstein S; Bergelson JM
J Virol; 2015 Jan; 89(2):1324-8. PubMed ID: 25392210
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of coxsackie B virus infection by soluble forms of its receptors: binding affinities, altered particle formation, and competition with cellular receptors.
Goodfellow IG; Evans DJ; Blom AM; Kerrigan D; Miners JS; Morgan BP; Spiller OB
J Virol; 2005 Sep; 79(18):12016-24. PubMed ID: 16140777
[TBL] [Abstract][Full Text] [Related]
7. Dynamin- and lipid raft-dependent entry of decay-accelerating factor (DAF)-binding and non-DAF-binding coxsackieviruses into nonpolarized cells.
Patel KP; Coyne CB; Bergelson JM
J Virol; 2009 Nov; 83(21):11064-77. PubMed ID: 19710132
[TBL] [Abstract][Full Text] [Related]
8. Coxsackie B viruses that use human DAF as a receptor infect pig cells via pig CAR and do not use pig DAF.
Spiller OB; Goodfellow IG; Evans DJ; Hinchliffe SJ; Morgan BP
J Gen Virol; 2002 Jan; 83(Pt 1):45-52. PubMed ID: 11752699
[TBL] [Abstract][Full Text] [Related]
9. Human astrocytic cells support persistent coxsackievirus B3 infection.
Zhang X; Zheng Z; Shu B; Liu X; Zhang Z; Liu Y; Bai B; Hu Q; Mao P; Wang H
J Virol; 2013 Nov; 87(22):12407-21. PubMed ID: 24027313
[TBL] [Abstract][Full Text] [Related]
10. Kinetic and structural analysis of coxsackievirus B3 receptor interactions and formation of the A-particle.
Organtini LJ; Makhov AM; Conway JF; Hafenstein S; Carson SD
J Virol; 2014 May; 88(10):5755-65. PubMed ID: 24623425
[TBL] [Abstract][Full Text] [Related]
11. Cardiovirulent coxsackieviruses and the decay-accelerating factor (CD55) receptor.
Martino TA; Petric M; Brown M; Aitken K; Gauntt CJ; Richardson CD; Chow LH; Liu PP
Virology; 1998 May; 244(2):302-14. PubMed ID: 9601501
[TBL] [Abstract][Full Text] [Related]
12. Comparative analysis of virus-host cell interactions of haemagglutinating and non-haemagglutinating strains of coxsackievirus B3.
Pasch A; Küpper JH; Wolde A; Kandolf R; Selinka HC
J Gen Virol; 1999 Dec; 80 ( Pt 12)():3153-3158. PubMed ID: 10567646
[TBL] [Abstract][Full Text] [Related]
13. Coxsackievirus B3 Infection of Human iPSC Lines and Derived Primary Germ-Layer Cells Regarding Receptor Expression.
Böhnke J; Pinkert S; Schmidt M; Binder H; Bilz NC; Jung M; Reibetanz U; Beling A; Rujescu D; Claus C
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33513663
[TBL] [Abstract][Full Text] [Related]
14. Interaction of decay-accelerating factor with echovirus 7.
Plevka P; Hafenstein S; Harris KG; Cifuente JO; Zhang Y; Bowman VD; Chipman PR; Bator CM; Lin F; Medof ME; Rossmann MG
J Virol; 2010 Dec; 84(24):12665-74. PubMed ID: 20881044
[TBL] [Abstract][Full Text] [Related]
15. Heparan sulfates and coxsackievirus-adenovirus receptor: each one mediates coxsackievirus B3 PD infection.
Zautner AE; Körner U; Henke A; Badorff C; Schmidtke M
J Virol; 2003 Sep; 77(18):10071-7. PubMed ID: 12941917
[TBL] [Abstract][Full Text] [Related]
16. Attachment of coxsackievirus B3 variants to various cell lines: mapping of phenotypic differences to capsid protein VP1.
Schmidtke M; Selinka HC; Heim A; Jahn B; Tonew M; Kandolf R; Stelzner A; Zell R
Virology; 2000 Sep; 275(1):77-88. PubMed ID: 11017789
[TBL] [Abstract][Full Text] [Related]
17. Molecular determinants of disease in coxsackievirus B1 murine infection.
Cifuente JO; Ferrer MF; Jaquenod de Giusti C; Song WC; Romanowski V; Hafenstein SL; Gómez RM
J Med Virol; 2011 Sep; 83(9):1571-81. PubMed ID: 21739448
[TBL] [Abstract][Full Text] [Related]
18. Comparative analysis of two coxsackievirus B3 strains: putative influence of virus-receptor interactions on pathogenesis.
Selinka HC; Wolde A; Pasch A; Klingel K; Schnorr JJ; Küpper JH; Lindberg AM; Kandolf R
J Med Virol; 2002 Jun; 67(2):224-33. PubMed ID: 11992583
[TBL] [Abstract][Full Text] [Related]
19. Single amino acid changes in the virus capsid permit coxsackievirus B3 to bind decay-accelerating factor.
Pan J; Narayanan B; Shah S; Yoder JD; Cifuente JO; Hafenstein S; Bergelson JM
J Virol; 2011 Jul; 85(14):7436-43. PubMed ID: 21561916
[TBL] [Abstract][Full Text] [Related]
20. Exosomes mediate Coxsackievirus B3 transmission and expand the viral tropism.
Fu Y; Xiong S
PLoS Pathog; 2023 Jan; 19(1):e1011090. PubMed ID: 36634130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
